Initial experience with bosentan for the management of pulmonary hypertension after heart transplantation.
Evelyn Santiago-VacasMarta FarreroJuan B Ivey-MirandaMaria Ángeles CastelAna García-ÁlvarezJosé RiosFelix Perez-VillaPublished in: Clinical transplantation (2018)
Bosentan, initiated early post-transplant, was associated with a significant decrease in PVR. Bosentan was well tolerated and did not interact with immunosuppressive treatment.